Skip to content

Haleon

US · HLN #553 by market cap Listed 2022
9.02 +0.15 +1.69%
Live - 5344 symbols - heartbeat 23s ago · 2026-10-08 07:38
Pre-market 9.08 +0.67%
After-hours 9.02 0.00%
Overnight 9.07 +0.55%
Market cap
39.67B
P/B
1.83
EPS
0.49
Reader sentiment Are you bullish or bearish on HLN?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Fair Value how this is computed

Below fair value
9.69 fair value ≈ 12.00 14.30
  • Implied fair-value range of 9.69-14.30, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is -24.8% below the average-multiple fair value of 12.00.

Valuation each multiple against its own 5-year range

P/B ratio 1.82 Cheap vs history 27th percentile
5-year average 1.84 · #38 of 71 in Drug Manufacturers - Specialty & Generic
P/E ratio 18.75 Cheap vs history 10th percentile
5-year average 24.53 · forward 16.36 · #12 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 2.69 Cheap vs history 25th percentile
5-year average 2.87 · forward 2.57 · #44 of 80 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Haleon (HLN) 39.67B 18.87 1.83 2.11%
Takeda Pharmaceutical (TAK) 58.68B -55.67 1.23 3.26%
Teva Pharmaceutical Industries (TEVA) 45.70B 65.30 5.89 0.00%
Zoetis (ZTS) 29.57B 11.67 9.39 2.88%
United Therapeutics (UTHR) 23.38B 19.53 3.65 0.00%
Viatris (VTRS) 20.09B -47.27 1.41 2.74%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value10.45 Economic moatWide UncertaintyLow

Trading 15.9% below Morningstar's fair value estimate.

Fair value

Haleon PLC receives a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 14% discount to our quantitative fair value estimate of $10.45 per share, which is reinforced by this estimate's low uncertainty rating.

The firm's profitability increases our estimated valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 18.9, which sits in the bottom 40% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be cheap.

The firm's liquidity is an additional encouraging factor. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. The firm's median trading volume over the past 60 days, a core component of liquidity, falls in the top 10% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. This characteristic further promotes our favorable price/fair value ratio.

Economic moat

The company's wide quantitative moat rating suggests a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 07:38:25 · For reference only, not investment advice and not tailored to your situation.